AR125477A1 - Compuestos heterocíclicos capaces de activar sting - Google Patents
Compuestos heterocíclicos capaces de activar stingInfo
- Publication number
- AR125477A1 AR125477A1 ARP220101113A ARP220101113A AR125477A1 AR 125477 A1 AR125477 A1 AR 125477A1 AR P220101113 A ARP220101113 A AR P220101113A AR P220101113 A ARP220101113 A AR P220101113A AR 125477 A1 AR125477 A1 AR 125477A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- group
- heterocyclyl containing
- membered bicyclic
- atom
- Prior art date
Links
- 230000003213 activating effect Effects 0.000 title abstract 2
- 150000002391 heterocyclic compounds Chemical class 0.000 title abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 19
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 10
- 125000002618 bicyclic heterocycle group Chemical group 0.000 abstract 9
- 125000005842 heteroatom Chemical group 0.000 abstract 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 3
- 229910052757 nitrogen Inorganic materials 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 abstract 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 abstract 1
- 108010050904 Interferons Proteins 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Compuestos heterocíclicos de la fórmula (1) capaces de activar STING (estimulador de genes de interferón). Reivindicación 1: Un compuesto caracterizado porque tienen la fórmula (1) en donde A es N o C, B es un grupo seleccionado del grupo que consiste en un heterociclilo monocíclico de 5 - 7 miembros que contiene 1 o 2 átomos de N, un heterociclilo bicíclico de 6 miembros que contiene 1 átomo de N, un heterociclilo bicíclico de 7 - 11 miembros que contiene 2 átomos de N, un heterociclilo bicíclico de 7 miembros que contiene 1 átomo de N y 1 átomo de O, un heterociclilo monocíclico de 6 miembros que contiene 1 átomo de N y 1 heteroátomo seleccionado del grupo que consiste en O y S, un heterociclilo bicíclico de 9 miembros que contiene 3 heteroátomos, 2 de los cuales son N y el otro es O, un heterociclilo bicíclico de 9 miembros que contiene 1 átomo de N y 1 átomo de S, un heterociclilo bicíclico de 10 miembros que contiene 3 átomos de N, 2 de los cuales están sustituidos con C₁₋₆ alquilo, fenilo, un heterociclilo bicíclico de 9 miembros que contiene 3 átomos de N, -C₁₋₄-alquileno-pirimidina, y -C₁₋₄-alquileno-O-C₁₋₃-alquilo; D es un grupo seleccionado del grupo que consiste en un heterociclilo bicíclico de 9 miembros que contiene 2 átomos de N, un heterociclilo bicíclico de 10 miembros que contiene 1 átomo de N, y benzodioxol; R¹ se selecciona del grupo que consiste en -H, -C₁₋₆-alquilo, -CF₃, -C₂₋₆- alquinilo, -O-C₁₋₆-alquilo y halógeno; R² se selecciona del grupo que consiste en -H, -C₁₋₆-alquilo, -C₁₋₆-alquilenoOH, -C(O)OH, -C(O)O-C₁₋₆-alquilo y -pirazolilo-C₁₋₆-alquilo; R³ es -H o -C₁₋₆-alquilo; R⁴ se selecciona del grupo que consiste en -H, -C₁₋₃-alquilo, -NH₂, -NHC₁₋₃- alquilo y N(C₁₋₃-alquilo)₂; R⁵ está ausente o se selecciona del grupo que consiste en -H, -C₁₋₆-alquilo, - S(O₂)-C₁₋₆-alquilo, -NH-S(O₂)-C₁₋₆-alquilo, =O, -C(O)-C₁₋₆-alquilo, -C(O)H, - C(O)OH, -C(O)NH₂, -C(O)O-C₁₋₆-alquilo, -NR⁵.¹R⁵.², -C₁₋₆-alquileno-C(O)OH, -S(O₂)- NH₂, -pirolidin-2-ona-1-ilo, -tetrazolilo, y un heteroarilo de 5 miembros con 1 o 2 heteroátomos seleccionados del grupo que consiste en N y O, sustituido con R⁵.³; R⁵.¹ se selecciona del grupo que consiste en -H, -C₁₋₆-alquilo, -C(O)-C₁₋₆-alquilo y -C₁₋₆-alquileno-O-C₁₋₆-alquilo; R⁵.² se selecciona del grupo que consiste en -H, -C₁₋₆-alquilo, -C(O)-C₁₋₆- alquilo, -C₁₋₆-alquileno-O-C₁₋₆-alquilo y -C₁₋₆-alqileno-R⁵.³; R⁵.³ se selecciona del grupo que consiste en -H, -C₁₋₆-alquilo y un heteroarilo de 6 miembros con 1 o 2 heteroátomos seleccionados de un grupo que consiste en N y O; R⁶ está ausente o se selecciona del grupo que consiste en -H, -C₁₋₆-alquilo, =O y -C(O)OH; o una sal de este. Reivindicación 15: Una composición farmacéutica caracterizada porque comprende al menos un compuesto de acuerdo con cualquiera de las reivindicaciones 1 a 11 o una sal aceptable desde el punto de vista farmacéutico de este y un portador aceptable desde el punto de vista farmacéutico.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21171155 | 2021-04-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR125477A1 true AR125477A1 (es) | 2023-07-19 |
Family
ID=75825418
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220101113A AR125477A1 (es) | 2021-04-29 | 2022-04-28 | Compuestos heterocíclicos capaces de activar sting |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US12065427B2 (es) |
| EP (1) | EP4330250A1 (es) |
| JP (1) | JP2024514361A (es) |
| KR (1) | KR20240004646A (es) |
| CN (2) | CN118546123A (es) |
| AR (1) | AR125477A1 (es) |
| AU (1) | AU2022265323C1 (es) |
| BR (1) | BR112023017873A2 (es) |
| CA (1) | CA3214127A1 (es) |
| CL (1) | CL2023002959A1 (es) |
| CO (1) | CO2023014672A2 (es) |
| CR (1) | CR20230509A (es) |
| DO (1) | DOP2023000234A (es) |
| EC (1) | ECSP23069018A (es) |
| IL (1) | IL307977A (es) |
| MX (1) | MX2023012800A (es) |
| PE (1) | PE20240069A1 (es) |
| TW (1) | TW202309031A (es) |
| WO (1) | WO2022229341A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024089155A1 (en) * | 2022-10-28 | 2024-05-02 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds as sting antagonists |
| WO2024209363A1 (en) | 2023-04-06 | 2024-10-10 | Pfizer Inc. | Substituted indazole propionic acid derivative compounds and uses thereof as ampk activators |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR090151A1 (es) | 2012-03-07 | 2014-10-22 | Lilly Co Eli | Compuestos inhibidores de raf |
| US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| TWI848953B (zh) | 2018-06-09 | 2024-07-21 | 德商百靈佳殷格翰國際股份有限公司 | 針對癌症治療之多特異性結合蛋白 |
| EP3817820A1 (en) | 2018-07-03 | 2021-05-12 | IFM Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| TW202028183A (zh) | 2018-10-10 | 2020-08-01 | 大陸商江蘇豪森藥業集團有限公司 | 含氮雜芳類衍生物調節劑、其製備方法和應用 |
| SG11202103573YA (en) | 2018-10-11 | 2021-05-28 | Ono Pharmaceutical Co | STING Agonistic Compound |
| CN113563313B (zh) * | 2019-01-31 | 2022-11-04 | 成都先导药物开发股份有限公司 | 一种免疫调节剂 |
| CN112521394A (zh) * | 2019-09-19 | 2021-03-19 | 中国药科大学 | 杂环酰胺类化合物、其可药用的盐及其制备方法和用途 |
| CA3155569A1 (en) * | 2019-09-25 | 2021-04-01 | Pfizer Inc. | Polyheterocyclic modulators of sting (stimulator of interferon genes) |
| TW202128756A (zh) | 2019-10-02 | 2021-08-01 | 德商百靈佳殷格翰國際股份有限公司 | 用於癌症治療之多重專一性結合蛋白 |
| CN112869927A (zh) | 2019-11-29 | 2021-06-01 | 百安健康复医疗（深圳）有限公司 | 用于治疗膝骨性关节炎的矫正器 |
| CN114761394B (zh) | 2020-01-16 | 2024-03-29 | 浙江海正药业股份有限公司 | 吡啶或嘧啶类衍生物及其制备方法和用途 |
| AU2021228767A1 (en) | 2020-02-28 | 2022-09-29 | Remix Therapeutics Inc. | Heterocyclic amides and their use for modulating splicing |
-
2022
- 2022-04-27 US US17/730,395 patent/US12065427B2/en active Active
- 2022-04-28 KR KR1020237040758A patent/KR20240004646A/ko unknown
- 2022-04-28 IL IL307977A patent/IL307977A/en unknown
- 2022-04-28 JP JP2023564644A patent/JP2024514361A/ja active Pending
- 2022-04-28 MX MX2023012800A patent/MX2023012800A/es unknown
- 2022-04-28 PE PE2023002941A patent/PE20240069A1/es unknown
- 2022-04-28 CN CN202410587835.5A patent/CN118546123A/zh active Pending
- 2022-04-28 CA CA3214127A patent/CA3214127A1/en active Pending
- 2022-04-28 TW TW111116155A patent/TW202309031A/zh unknown
- 2022-04-28 AR ARP220101113A patent/AR125477A1/es unknown
- 2022-04-28 EP EP22727008.9A patent/EP4330250A1/en active Pending
- 2022-04-28 WO PCT/EP2022/061379 patent/WO2022229341A1/en active Application Filing
- 2022-04-28 BR BR112023017873A patent/BR112023017873A2/pt unknown
- 2022-04-28 CN CN202280030669.8A patent/CN117255784A/zh active Pending
- 2022-04-28 AU AU2022265323A patent/AU2022265323C1/en active Active
- 2022-04-28 CR CR20230509A patent/CR20230509A/es unknown
-
2023
- 2023-09-13 EC ECSENADI202369018A patent/ECSP23069018A/es unknown
- 2023-10-03 CL CL2023002959A patent/CL2023002959A1/es unknown
- 2023-10-20 DO DO2023000234A patent/DOP2023000234A/es unknown
- 2023-10-30 CO CONC2023/0014672A patent/CO2023014672A2/es unknown
-
2024
- 2024-03-06 US US18/596,986 patent/US20240270718A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN118546123A (zh) | 2024-08-27 |
| EP4330250A1 (en) | 2024-03-06 |
| US12065427B2 (en) | 2024-08-20 |
| US20240270718A1 (en) | 2024-08-15 |
| BR112023017873A2 (pt) | 2023-12-12 |
| CR20230509A (es) | 2023-12-07 |
| CA3214127A1 (en) | 2022-11-03 |
| AU2022265323C1 (en) | 2024-09-12 |
| DOP2023000234A (es) | 2023-11-30 |
| KR20240004646A (ko) | 2024-01-11 |
| AU2022265323A1 (en) | 2023-09-14 |
| MX2023012800A (es) | 2023-11-08 |
| WO2022229341A1 (en) | 2022-11-03 |
| AU2022265323B2 (en) | 2024-05-16 |
| ECSP23069018A (es) | 2023-10-31 |
| PE20240069A1 (es) | 2024-01-11 |
| TW202309031A (zh) | 2023-03-01 |
| CN117255784A (zh) | 2023-12-19 |
| CL2023002959A1 (es) | 2024-03-01 |
| JP2024514361A (ja) | 2024-04-01 |
| IL307977A (en) | 2023-12-01 |
| CO2023014672A2 (es) | 2023-11-10 |
| US20220388986A1 (en) | 2022-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR125477A1 (es) | Compuestos heterocíclicos capaces de activar sting | |
| PE20190705A1 (es) | COMPUESTOS DE BENZO[b] TIOFENO COMO AGONISTAS DE STING | |
| PE20181045A1 (es) | Compuestos utiles como inmunomoduladores | |
| PE20211655A1 (es) | Compuestos de 6-azabencimidazol sustituidos como inhibidores de hpk1 | |
| PE20240775A1 (es) | Compuestos antivirales | |
| ATE117553T1 (de) | Substituierte dihydroisochinolinone und verwandte verbindungen als verstärker der letalen effekte von bestrahlung und bestimmten chemotherapeutika; ausgewählte verbindungen, analoga und verfahren. | |
| AR100645A1 (es) | Derivados de pirazolo-pirimidina | |
| AR094537A1 (es) | COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa | |
| AR036046A1 (es) | Inhibidores de la hiv proteasa, composiciones que las contienen y sus usos farmaceuticos | |
| AR094452A1 (es) | COMPUESTOS HETEROCÍCLICOS SUSTITUIDOS CON AMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O INFa | |
| AR047076A1 (es) | Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas | |
| AR065937A2 (es) | Compuesto derivado indazol, composicion farmaceutica que lo comprende y su uso en la fabricacion de medicamentos para modular la actividad de proteina quinasa | |
| AR087046A2 (es) | Compuestos derivados de 4-oxoquinolina | |
| AR111407A1 (es) | Compuestos inhibidores de ask1 y usos de los mismos | |
| AR110789A1 (es) | Compuestos moduladores del receptor de hidrocarburos de arilo (ahr) | |
| AR017844A1 (es) | Derivados de benzamidina, procedimiento para prepararlos, empleo de los mismos para preparar un medicamento, composicion farmaceutica que los contiene yprocedimiento para obtenerla | |
| CY1115171T1 (el) | Ιατρικο φαρμακο | |
| AR035580A1 (es) | Compuestos inhibidores de ifata, compuestos intermediarios, procedimientos de preparacion y su uso en la preparacion de medicamentos | |
| PE20181017A1 (es) | Compuestos heteroarilo y su uso como farmacos terapeuticos | |
| AR118358A1 (es) | Derivados de pirimidona de anillo fusionado para uso en el tratamiento de infección por hbv o enfermedades inducidas por hbv | |
| PE20211769A1 (es) | Compuestos heteroaromaticos como inhibidores de vanina | |
| AR120982A1 (es) | Derivados heterocíclicos activos como plaguicidas con sustituyentes que contienen azufre | |
| PE20220704A1 (es) | Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmaceuticas que los contienen y sus usos como agentes proapoptoticos | |
| CO5580782A2 (es) | Antibioticos de glicopeptido-cefalosporina entrecruzados | |
| PE20220252A1 (es) | Compuestos de pirrol |